Drug Profile


Alternative Names: Andante; Detantol; E 1015; E 643; EA 0643

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eisai Co Ltd
  • Developer Boehringer Ingelheim; Eisai Co Ltd; Santen Pharmaceutical
  • Class Antihypertensives; Eye disorder therapies; Quinazolines; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Glaucoma; Heart failure; Hypertension; Ocular hypertension

Most Recent Events

  • 07 Nov 2001 Launched for Glaucoma in Japan (Ophthalmic)
  • 07 Nov 2001 Launched for Ocular hypertension in Japan (Ophthalmic)
  • 19 Jun 2001 Registered for Glaucoma in Japan (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top